Athersys to Present at 2018 Cell & Gene Meeting on the Mesa
September 24 2018 - 6:00AM
CEO invited to provide corporate overview
and speak in two workshops focusing on innovative development
initiatives in Japan and advanced manufacturing
technologies
Athersys, Inc. (NASDAQ: ATHX) announced today that Gil Van
Bokkelen, Chairman and CEO, will present at the annual Cell &
Gene Meeting on the Mesa to be held October 3rd-5th in La Jolla,
California.
Dr. Van Bokkelen will provide a brief overview
of the Athersys’ clinical pipeline, focusing on the ongoing Phase 3
trial of MultiStem® cell therapy for the treatment of ischemic
stroke that has received Fast Track and RMAT designation from the
U.S. Food and Drug Administration, positive scientific advice from
the European Medicines Agency, and is being conducted under a
Special Protocol Assessment (SPA).
In addition, Dr. Van Bokkelen has been invited
to speak at two conference workshops, where he will describe the
Company’s progress working in collaboration with Healios K.K. under
the innovative regenerative medicine regulatory framework
implemented in Japan as part of the “Doing Business in Japan”
workshop. During the “Readiness Strategies for Cell Therapy –
Commercial Manufacturing” workshop, Dr. Van Bokkelen will discuss
commercial manufacturing approaches and technologies for cellular
therapies.
This conference is the largest partnering
meeting organized specifically for the cell and gene therapy
sector, providing the opportunity for participants to establish key
relationships and accelerate business development. Organized by the
Alliance for Regenerative Medicine and the Sanford Stem Cell
Clinical Center at the University of California-San Diego, the Cell
& Gene Meeting on the Mesa is a three-day conference featuring
three distinct parts, the program’s two-day Partnering Forum, a
Public Forum lecture and a full-day Scientific Symposium. The
event’s Partnering Forum on October 3rd-4th features more than 70
dedicated company presentations in addition to over 90 panelists
and featured speakers.
The following are specific details regarding
Athersys’ presentations at the conference:
Event:
|
Doing Business in
Japan Workshop: Development of an “Off the Shelf”
Cell Therapy for Ischemic Stroke and Other Indications Under the
Regenerative Medicine Regulatory Framework in Japan |
Date: |
October 3, 2018 |
Time: |
7:50 – 8:05 am Pacific Time |
Location: |
Magnolia Room at the Estancia La Jolla Hotel & Spa, 9700 North
Torrey Pines Road, La Jolla, CA 92037 |
Event: |
Athersys Corporate
Overview |
Date: |
October 3, 2018 |
Time: |
5:30 – 5:45 pm Pacific Time |
Location: |
Ballroom 1 at the Estancia La Jolla Hotel & Spa, 9700 North
Torrey Pines Road, La Jolla, CA 92037 |
Event:
|
Readiness
Strategies for Cell Therapy – Commercial Manufacturing Workshop,
Section 3 Technology |
Date: |
October 4, 2018 |
Time: |
8:10 – 8:35 am Pacific Time |
Location: |
Learning Theater at the Estancia La Jolla Hotel & Spa, 9700
North Torrey Pines Road, La Jolla, CA 92037 |
A live video webcast of all company
presentations and workshops will be available at:
http://www.meetingonthemesa.com/webcast and will also be
published on the conference website shortly after the event.
Please visit www.meetingonthemesa.com for full
information including registration. Complimentary attendance at
this event is available for credentialed investors and members of
the media only. Investors should contact Laura Parsons at
lparsons@alliancerm.org and interested media should contact Lyndsey
Scull at lscull@alliancerm.org.
About MultiStem
MultiStem cell therapy is a patented
regenerative medicine product in clinical development that has
shown the ability to promote tissue repair and healing in a variety
of ways, such as through the production of therapeutic factors
produced in response to signals of inflammation and tissue damage.
MultiStem’s potential for multidimensional therapeutic impact
distinguishes it from traditional biopharmaceutical therapies that
are typically focused on a single mechanism of benefit. The therapy
represents a unique “off-the-shelf” stem cell product that can be
manufactured in a scalable manner, may be stored for years in
frozen form, and is administered without tissue matching or the
need for immune suppression. Based upon its efficacy profile, its
novel mechanisms of action, and a favorable and consistent safety
profile demonstrated in clinical studies, MultiStem therapy could
provide a meaningful benefit to patients, including those suffering
from serious diseases and conditions with unmet medical need.
About Athersys
Athersys is an international biotechnology
company engaged in the development of therapeutic products designed
to extend and enhance the quality of human life. The Company is
developing its MultiStem® cell therapy product, a patented,
adult-derived "off-the-shelf" stem cell product, initially for
disease indications in the neurological, cardiovascular, and
inflammatory and immune disease areas, and has several ongoing
clinical trials evaluating this potential regenerative medicine
product. Athersys has forged strategic partnerships and a broad
network of collaborations to further advance MultiStem cell therapy
toward commercialization. More information is available at
www.athersys.com. Follow Athersys on Twitter at
www.twitter.com/athersys.
ATHX-G
Contact:
William (B.J.)
Lehmann
President and Chief Operating
Officer
Tel: (216) 431-9900bjlehmann@athersys.com
Karen Hunady Corporate Communications &
Investor RelationsTel: (216) 431-9900khunady@athersys.com
David Schull Russo Partners,
LLCTel: (212) 845-4271 or (858)
717-2310David.schull@russopartnersllc.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Sep 2023 to Sep 2024